J&J Unit Nabs FDA Approval for Glucose Monitoring System
The FDA has smiled on Johnson & Johnson unit Animas with its approval of the Animas Vibe insulin pump and continuous glucose monitoring system for the management of diabetes in children and adolescents, ages 2 to 17.
Featuring Dexcom G4 Platinum CGM technology, the system enables patients and their healthcare providers to view glucose data and administer insulin directly from the pump. This makes it easier to fine-tune insulin delivery, the company says.
Animas adds that the system is the only one available in the U.S. for patients as young as 2.
The system also has approval for children ages 2 and in parts of Europe, Australia, New Zealand and Canada. — Michael Cipriano